Pneumonia Clinical Trial
Official title:
Redefining Community Acquired Pneumonia in Older Adults: The Role and Impact of Aspiration
Verified date | November 2023 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will utilize diagnostic imaging and salivary biomarkers to estimate the prevalence of aspiration in older adults with suspected community-acquired bacterial pneumonia (CABP). 150 participants over the age of 60 diagnosed with pneumonia will be recruited into this study. 62 of these participants will be enrolled in a supplemental study.
Status | Completed |
Enrollment | 75 |
Est. completion date | July 2, 2023 |
Est. primary completion date | July 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Emergency Department (ED) Recruitment Inclusion Criteria: - 60 years of age or older - Patient has clinical criteria for pneumonia or is being treated for pneumonia as defined by abnormal chest imaging or receiving antibiotics for a chest infection or the provider thinks the patient has pneumonia or is planning to treat the patient for pneumonia. - Patient is clinically stable and able to safely drink water, per the emergency department provider - Ability to provide consent or the presence of a legally authorized representative (LAR) who can consent on behalf of the patient Exclusion Criteria: - Prisoner - Non-English speaking - Respiratory symptoms for 7 days or more Phone Recruitment Inclusion Criteria: - 60 years of age and older - Patient was diagnosed with or treated for pneumonia at UW Health in the past 6 months - Ability to provide consent or the presence of a legally authorized representative (LAR) who can consent on behalf of the patient Exclusion Criteria: - Prisoner - Non-English speaking |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | Gordon and Betty Moore Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Aspiration | As defined by VFSS and radionuclide salivagram imaging studies. | up to 6 months on study | |
Secondary | Salivary extensional viscosity | Extensional viscosity will be determined using an extensional rheometer (Thermo-Fisher CaBER) and will be recorded 3 times per sample. | Any point during follow up within 6 months of index visit | |
Secondary | Salivary Substance P Concentration | Substance P is a salivary protein | Any point during follow up within 6 months of index visit | |
Secondary | Salivary pH | Salivary pH will be measured using a digital pH meter. | Any point during follow up within 6 months of index visit | |
Secondary | Recurrent pneumonia | As assessed on medical chart review | Any point during follow up within 6 months of index visit | |
Secondary | Lung Ultrasound Findings for ED participants | Lung ultrasound exams will be compared between older adults with aspiration related pneumonia mimics and those with infectious pneumonia. Interpretation of ultrasound images will be performed by two ultrasound fellowship trained EM faculty, blinded to any clinical information. Each lung ultrasound view captured will be reviewed and interpreted descriptively. Lung ultrasound findings will be described with the following features: crisp or irregular pleural line, A line artifacts, isolated Z line artifacts, static air bronchograms, dynamic air bronchograms, tissue-like consolidation without bronchograms, coalescent B lines (presence and how many per interspace), discrete B lines (presence and how many per interspace), subpleural hypoechoic consolidation, and pleural effusion. | at ED visit, baseline | |
Secondary | Patient Reported Swallowing Function as measured by physical symptoms on SWAL-QOL | All participants will complete self report surveys at their first study visit. The physical symptoms question on the SWAL-QOL asks the participant to identify how often they experienced specific symptoms in the past month, from 1 (almost always) to 5 (never). The total score is transposed to 0-100 with higher scores indicating better swallowing function. | at Point of Care visit, up to 6 months | |
Secondary | Percent Viral vs. Bacterial Infection for ED participants | MeMed BV® test results for participants recruited in the ED. | at ED visit, baseline | |
Secondary | Respiratory Pressure | Maximum expiratory pressure and maximum inspiratory pressure will be measured using a handheld digital manometer. This test will take approximately 5 minutes. | Any point during follow up within 6 months of index visit | |
Secondary | Peak Expiratory Flow (PEF) | A handheld digital peak cough flow meter will be used to assess PEF to quantify cough function. This test will take approximately 3 minutes. | Any point during follow up within 6 months of index visit | |
Secondary | Forced Expiratory Volume (FEV1) | A handheld digital peak cough flow meter will be used to assess forced expiratory volume (FEV1) to quantify cough function. This test will take approximately 3 minutes. | Any point during follow up within 6 months of index visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 |